Liver Cancer Patients: Can Chemotherapy Lead to a Cure? (2026 Update)

Chemotherapy alone cannot be said to "cure" liver cancer, and in many cases surgery, transplantation, and local treatments must be combined depending on liver function and stage. That said, the 5-year relative survival rate for liver cancer in Korea is 40.4%, and outcomes vary widely from person to person depending on liver function and stage.

Key Takeaways

• The 5-year relative survival rate for liver cancer in Korea is 40.4% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry). This is a nationwide statistic, not figures from any single hospital.
• In the U.S., the SEER 5-year relative survival rate for liver and intrahepatic bile duct cancer is 21.9% (2016–2022). Both figures are population averages that reflect differences in screening systems and timing of detection.
• Beyond staging, liver cancer treatment decisions depend heavily on liver function grade (Child-Pugh) and portal pressure, so even tumors of the same size may allow for different treatment options depending on liver function.
• In advanced stages (vascular invasion or spread outside the liver), systemic drug therapy—typically a combination of an immune checkpoint inhibitor and an anti-angiogenic agent, or an oral targeted therapy—becomes the main approach, and the treatment goal often shifts from cure to disease control.
• Survival rates are population averages, not predictions for any individual's outcome, so patients should always discuss their post-chemotherapy course with their medical team.

Can Chemotherapy Alone Cure Liver Cancer?

• Systemic drug therapy (chemotherapy) for liver cancer is mainly used in advanced stages where the tumor has invaded blood vessels or spread outside the liver, and is often aimed at controlling the tumor rather than curing it.
• In very early and early stages (small tumors, few in number, good liver function), liver resection, transplantation, or radiofrequency ablation are considered as curative treatments first. In intermediate stages (multiple tumors within the liver), transarterial chemoembolization (TACE) becomes the central treatment.
• In advanced stages, combining an immune checkpoint inhibitor with an anti-angiogenic agent has become part of the standard first-line treatment, with oral targeted therapies used depending on conditions. Radiation therapy may also be combined for tumors that have invaded blood vessels.
• When liver function is significantly impaired, chemotherapy can further damage the liver, so symptom control, preserving liver function, and evaluating transplant eligibility may take priority instead.

How Are Treatment Outcomes Determined? (Liver Cancer Treatment Sequence)

• Step 1 – Diagnosis and staging: Diagnosis is made when contrast-enhanced CT or MRI shows blood flow patterns characteristic of liver cancer, together with tumor markers such as AFP. If imaging findings are ambiguous, a biopsy is performed.
• Step 2 – Three key evaluations: The number and size of tumors and whether there is vascular invasion, liver function grade (Child-Pugh), and overall physical condition are assessed together to determine the treatment category.
• Step 3 – Treatment by category: Very early and early stages follow resection, ablation, or transplantation; intermediate stage centers on embolization; advanced stage centers on systemic drug therapy.
• Step 4 – Follow-up after treatment: For the first 1–2 years after treatment, contrast-enhanced CT or MRI and AFP tests are repeated every few months, with intervals gradually extended afterward. If chronic hepatitis B or C is present, antiviral treatment and liver function tests continue for life.

How Long Do Side Effects From Chemotherapy Last?

• Nausea and vomiting are experienced by about 70–80% of patients during chemotherapy, typically appearing within 1–8 hours after administration and potentially lasting up to a week (National Cancer Information Center).
• White blood cell counts typically begin to drop about 1 week after treatment starts, reach their lowest point at 2 weeks, and recover by 3 weeks. During this period, a fever of 38°C or higher requires an emergency room visit (National Cancer Information Center, NCI).
• Peripheral neuropathy (numbness or tingling in the hands and feet) may continue after treatment ends or recover very slowly, depending on the drug and dose, so symptoms should be discussed with the medical team as soon as they begin.
• When immunotherapy is used in liver cancer treatment, inflammatory reactions affecting the thyroid, liver, intestines, or skin can appear with a delay, so scheduled tests are still needed even after returning home.

FAQ — Does the 40.4% Survival Rate Apply to My Case?

No. This figure is the average 5-year relative survival rate for the entire group of patients diagnosed with liver cancer in Korea between 2019 and 2023, and individual outcomes vary greatly depending on stage, liver function, and hepatitis status. Even tumors of the same size can lead to different treatment options and outcomes depending on liver function grade.

FAQ — Is Recurrence Monitoring Needed After Chemotherapy?

Yes. Because liver cancer can develop in other parts of the liver beyond the treated area, follow-up intervals tend to be more frequent than for many other cancers. It is common practice to repeat imaging tests and AFP tests every few months during the first 1–2 years after treatment.

Sources and Notes

• This article was written based on liver cancer reference notes (National Cancer Registration Statistics 2019–2023 · National Cancer Center Korea, SEER, NCCN patient guidelines) and chemotherapy side-effect management notes (National Cancer Information Center, U.S. National Cancer Institute NCI).
• This content is intended for general medical information purposes, and actual diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.